OncoMatch/Clinical Trials/NCT06788912
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Is NCT06788912 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for lung neoplasm malignant.
Treatment: Pembrolizumab (neoadjuvant) · Cisplatin · Gemcitabine · Pemetrexed · Sacituzumab tirumotecan · H1 receptor antagonist · H2 receptor antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Carboplatin · Pembrolizumab (adjuvant) · Paclitaxel · Steroid mouthwash (dexamethasone or equivalent) — The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR wild-type
Disease stage
Required: Stage II, IIIA, IIIB (N2)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Exception: prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids
Received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Southern Cancer Center (SCC) ( Site 8004) · Daphne, Alabama
- Sansum Clinic (Ridley Tree) ( Site 8012) · Santa Barbara, California
- Rocky Mountain Cancer Centers (RMCC) ( Site 8011) · Lone Tree, Colorado
- MedStar Franklin Square Medical Center ( Site 0033) · Baltimore, Maryland
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8006) · Eugene, Oregon
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06788912 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB (N2) is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify